Meeting
2021 ASCO Annual Meeting
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
Authors
Camille Catherine Jackson
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Camille Catherine Jackson , Leigh Cantrell , Britt Kristina Erickson , Kathleen N. Moore , Linda R. Duska , Debra L. Richardson , Lisa Michelle Landrum , Laura L. Holman , Joan L. Walker , Robert S. Mannel , Katherine M. Moxley , Lurdes Queimado , Kai Ding , Andrew Cohoon , Sara Vesely , Lauren E. Dockery
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT03476798
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5527)
DOI
10.1200/JCO.2021.39.15_suppl.5527
Abstract #
5527
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.
First Author: Helen Mackay
Poster
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
First Author: Bradley Corr
First Author: B.J. Rimel
Poster
2022 ASCO Annual Meeting
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
First Author: JUNG-YUN LEE